Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors: Role of suppression of endogenous endothelin secretion

Circulation

Volumn 94, Issue 7, 1996, Pages 1752-1761

  Brunner, Friedrich ^a   Kukovetz, Walter R ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

angiotensin; arrhythmia; endothelin; hemodynamics; ischemia; reperfusion

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ANGIOTENSIN; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ICATIBANT; LACTATE DEHYDROGENASE; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHORAMIDON; RAMIPRILAT;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RHYTHM; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMICS; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029740607     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.7.1752     Document Type: Article

References (49)

1. De Graeff PA, Van Gilst WH, Bel K, De Langen CDJ, Kingma JH, Wesseling H. Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol. 1987;9(suppl 2): S37-S42.
2. Cargnoni A, Boraso A, Scotti C, Ghirardelli N, Benigno M, Bernocchi P, Pedersini P, Ferrari R. Effect of angiotensin converting enzyme inhibition with quinaprilat on the ischaemic and reperfused myocardium. J Mol Cell Cardiol. 1994;26:69-86.
3. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418.
4. De Graeff PA, van Gilst WH, De Langen CDJ, Wesseling H. Concentration dependent protection by captopril against reperfusion injury in the isolated rat heart. Circulation, 1984;70(suppl II):II-89. Abstract.
5. Linz W, Schölkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8(suppl 10):S91-S99.
6. Linz W, Martorana PA, Schölkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol. 1990;15(suppl 6):S99-S109.
7. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
8. Wiemer G, Schölkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 1994;28:166-172.
9. Linz W, Wiemer G, Schölkens BA. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol. 1992;24:909-919.
10. Mombouli J-V, Nephtali M, Vanhoutte PM. Effects of the converting enzyme inhibitor cilazaprilat on endothelium-dependent responses. Hypertension. 1991;18(suppl II):II-22-II-29.
11. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
12. Krämer BK, Nishida M, Kelly RA, Smith TW. Endothelins: myocardial actions of a new class of cytokines. Circulation. 1992;85:350-356.
13. Yorikane R, Shiga H, Miyake S, Koike H. Evidence for direct arrhythmogenic action of endothelin. Biochem Biophys Res Commun. 1990;173:457-462.
14. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, Shichiri M, Marumo F. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension. 1991;18:165-170.
15. Yoshida H, Nakamura M. Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells. Life Sci. 1992;50:195-200.
16. Yokokawa K, Kohno M, Yasunari K, Murakawa K-i, Takeda T. Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells. Hypertension. 1991;18:304-315.
17. Douglas SA, Edwards RM, Elliott JD, Ohlstein EH. In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. Br J Pharmacol. 1995;114:405-413.
18. Doherty AM, Cody WL, He JX, DePue PL, Cheng X-M, Welch KM, Flynn MA, Reynolds EE, LaDouceur DM, Davis LS, Keiser JA, Haleen SJ. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol. 1993;22(suppl 8): S98-S102.
19. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473-485.
20. 2+ concentration on endothelin-1 secretion. FEBS Lett. 1994;350:33-36.
21. Wienen W, Kammermeier H. Intra- and extracellular markers in interstitial transudate of perfused rat hearts. Am J Physiol. 1988;254:H785-H794.
22. Brunner F. Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. J Mol Cell Cardiol. 1995;27:1953-1963.
23. + loss and arrhythmias in rat hearts: effect of glibenclamide, a sulfonylurea. Circ Res. 1990;66:478-485.
24. Brunner F, du Toit EF, Opie LH. Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol. 1992;24:1291-1305.
25. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
26. Opgenorth TJ, Wu-Wong JR, Shiosaki K. Endothelin-converting enzymes. FASEB J. 1992;6:2653-2659.
27. Hearse DJ, Humphrey SM. Enzyme release during myocardial anoxia: a study of metabolic protection. J Mol Cell Cardiol. 1975;7:463-482.
28. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991;68:905-921.
29. Gavras H. Angiotensin-converting enzyme inhibition and the heart. Hypertension. 1994;23:813-818.
30. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol. 1984;16:497-518.
31. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
32. Schölkens BA, Linz W, König W. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J Hypertens. 1988;6:S25-S28.
33. Hasdai D, Kornowski R, Battler A. Endothelin and myocardial ischemia. Cardiovasc Drugs Ther. 1994;8:589-599.
34. Karwatowska-Prokopczuk E, Wennmalm A. Effects of endothelin on coronary flow, mechanical performance, oxygen uptake, and formation of purines and on outflow of prostacyclin in the isolated rabbit heart. Circ Res. 1990;66:46-54.
35. Salvati P, Chierchia S, Dho L, Ferrario RG, Parenti P, Vicedomini G, Patrono C. Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol 1991;17:1007-1014.
36. Han H, Neubauer S, Braecker B, Ertl G. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart: attenuation of ischemic injury by the endothelin-1 antagonists BQ123 and BQ610. J Mol Cell Cardiol, 1995;27:761-766.
37. Lindpaintner K, Jin M, Niedermeyer N, Wilhelm MJ, Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res. 1990;67:564-573.
38. Chua BHL, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 messenger RNA by angiotensin-II in rat heart endothelial cells. Biochim Biophys Acta. 1993;1178:201-206.
39. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
40. Enous R, Opie LH. Effect of the angiotensin-converting enzyme inhibitor, perindoprilat, and of angiotensin-II on the transient inward current of rabbit ventricular myocytes. Cardiovasc Drugs Ther. 1994;8:647-651.
41. Momose N, Fukuo K, Morimoto S, Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. Hypertension. 1993;21:921-924.
42. 2+ from a caffeine- and ryanodine-insensitive intracellular pool in rat atrial cells. J Biol Chem. 1990;265:6782-6787.
43. Aiello EA, Jabr RI, Cole WC. Arrhythmia and delayed recovery of cardiac action potential during reperfusion after ischemia: role of oxygen radical-induced no-reflow phenomenon. Circ Res. 1995;77:153-162.
44. Harada K, Miwa A, Kaneta S, Izawa T, Fukushima H, Ogawa N. Effects of KRN 2391, nicorandil and diltiazem on the changes in the electrocardiogram caused by endothelin-1 in anaesthetized rats. Br J Pharmacol. 1993;109:679-684.
45. 2. Br J Pharmacol. 1884;112:963-971.
46. Van Heugten HAA, Bezstarosti K, Lamers JMJ. Endothelin-1 and phenylephrine-induced activation of the phosphoinositide cycle increases cell injury of cultured cardiomyocytes exposed to hypoxia/reoxygenation. J Mol Cell Cardiol. 1994;26:1513-1524.
47. Douglas SA, Meek TD, Ohlstein EH. Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol Sci. 1994;15:313-316.
48. Juggi JS, Koenig-Berard E, van Gilst WH. Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors. Can J Cardiol. 1993;9:336-352.
49. Opie LH, Kowolik H. The discovery of captopril: from large animals to small molecules. Cardiovasc Res. 1995;30:18-25.